Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$72.43-0.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TECH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 38.9% |
| Our one-year growth estimate | diamond | 7.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 31.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TECH — dividend update
Dated 2026-08-12
Other Events A copy of the press release issued by Bio-Techne Corporation on August 12, 2026 announcing a cash dividend is attached hereto as Exhibit 99.2.
Why it matters: Keeping the $0.08 dividend is important. It helps build investor trust and manage funds.
Supportive ifManagement confirms the dividend will be maintained in the next earnings call.
Worry ifManagement announces a cut to the dividend in the next earnings call.
Why it matters: Finding cost savings is key for making more money after the acquisition. It can help financial performance.
Supportive ifMerck KGaA reports achieving EUR 140 million in annual cost synergies by year 3.
Worry ifCost synergies fall short of EUR 140 million or take longer than expected to realize.
Why it matters: Stable or growing revenue shows recovery and market strength. This is important for investor trust.
Supportive ifOrganic revenue growth exceeds 0% in the next quarter.
Worry ifOrganic revenue declines again in the next quarter.
Why it matters: Changes in leadership can change strategy and performance. Watching this helps understand future plans.
Watch forNew leaders announce plans that match growth goals.
Also watch forLeadership changes can cause uncertainty or slow down strategic plans.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$36 on $10,000 · ±0.4% | How much price usually moves either way. |
| Bad day | $390 loss on $10,000 · 3.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,936 loss on $10,000 · 39.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good organic growth would show demand is recovering. This happens in mixed market conditions.
Supportive ifQ1 FY2027 organic revenue growth exceeds 2% year over year.
Worry ifQ1 FY2027 organic revenue declines or remains flat year over year.
Why it matters: Sustained growth in large pharma is crucial for Bio-Techne's overall performance. It shows demand in a key market.
Supportive ifLarge pharma segment reports double-digit growth for the next quarter.
Worry ifLarge pharma growth falls below double digits in the next report.
Why it matters: The new leadership could change how the Diagnostics segment performs and plans.
Watch forThe Diagnostics segment shows better revenue growth after the leadership change.
Also watch forThe Diagnostics segment continues to show declining or flat revenue growth.
Why it matters: New leaders in Diagnostics and Spatial Biology may change the strategy. This could affect performance.
Watch forPerformance metrics get better with new leadership.
Also watch forPerformance metrics get worse with new leadership.
Why it matters: Trends in adjusted EPS can show how profitable and efficient the company is.
Watch forAdjusted EPS increases above $0.53 in the next quarter.
Also watch forAdjusted EPS decreases below $0.52 in the next quarter.
Why it matters: Keeping the dividend shows financial health. It shows a commitment to shareholders.
Watch forThe dividend remains at $0.08 per share in the next update.
Also watch forThe dividend is cut below $0.08 per share in the next update.
Why it matters: Stable revenue growth shows recovery in the biotech market. It can support long-term growth.
Supportive ifQ4 revenue growth returns to at least flat year-over-year after a 2% decline in Q3.
Worry ifQ4 revenue drops more than last year. This shows ongoing market challenges.
Why it matters: The acquisition could improve Bio-Techne's skills and market size. It may also bring quick financial gains.
Supportive ifThe acquisition will close by early 2027 after getting all approvals.
Worry ifThe acquisition may face big delays or not get the needed approvals.
Why it matters: A decline in sector revenue growth could signal broader challenges for Bio-Techne.
Worry ifSector revenue growth falls below its median of 5% year over year.
Less concerning ifSector revenue growth remains above its median of 5% year over year.
Why it matters: Better profits could improve financial health and boost investor trust.
Supportive ifThe operating margin will go above 33% in the next quarters.
Worry ifAdjusted operating margin falls or stays below 32% in the next quarters.
Why it matters: New leaders can change company plans. This can impact how well the company does.
Watch forSteve Crouse uses new strategies. This leads to better segment performance.
Also watch forLeadership changes cause confusion. This leads to worse segment performance.
Why it matters: Better margins show good cost management and profit efforts. These are key for long-term success.
Supportive ifOperating margin goes above 32.2% in the next quarter.
Worry ifOperating margin drops below 32.2% in the next quarter.
Why it matters: This report will show if revenue growth is improving after the recent earnings miss.
Watch forQ2 revenue grew more than 5% compared to last year. This shows recovery.
Also watch forQ2 revenue growth falls below 0%, confirming ongoing challenges.